ISPE Singapore has announced its resumption after a 2 year hiatus
ISPE Singapore Affiliate has announced the resumption of its annual Conference & Exhibition in-person and onsite from 18-19 August.
After a 2 year hiatus when the event was held online, this year's edition will be livestreamed and include a Pre-conference Symposium Online on 17 August.
The 3-day programme features 89 industry leaders, regulators and subject matter experts on its speaker faculty. Keynote speakers include:
The Main Conference is co-located with the Exhibition, 'Power Hour' talks, 'Ask the Expert' Q&A sessions, In-depth Workshops programme and networking events.
"In Asia, ISPE Singapore Affiliate's annual conference is well positioned to offer unique and high-level learning and networking opportunities. Our mission is to connect knowledge from various parties, including regulators, subject matter experts, and key decision-makers. From digital transformation efforts, to navigating regulatory inspections post-pandemic, and to BioPharma-specific growth strategies, ISPE continues to provide valuable insights to the industry," said Shanshan Liu, ISPE Singapore Affiliate President.
Geoffrey Brown, Conference Chair, added: "As we emerge from COVID-19, we reflect upon the impact of long-term changes to healthcare and specifically the bio / pharmaceutical industry. This year's theme should come as no surprise: 'Collaboration | Transformation | Digitalization'."
"In the race to deliver medicines and treatments amidst global lockdowns, what strategies, operations and practices enabled or hindered our response?" Brown added. "How rigorous, agile and prepared are our processes and technologies to equip us for future pandemics?"
BioPharma growth forecasts for Asia remains upbeat, with growth within the Asia Pacific region anticipated to hit high single digits to low double digits year on year. Post-pandemic, the development of COVID-19 therapeutics and vaccines continues to be a key driver for mRNA technologies. Digital transformation and increased management of external providers, such as CDMOs, continue to be of focus. Meanwhile, methods of pharmaceutical regulatory inspection are in flux, as regulatory bodies implement hybrid inspections. These trends lend a highly dynamic backdrop for the growth conditions of BioPharma in Asia.
The affiliate's last onsite, in-person event in 2019 attracted a record 1000+ participants, while online editions in 2020-2021 grew to over 980 attendees. This strong presence of pharmaceutical manufacturers was supported in equal measure by regulators, EPCM, and various other stakeholders and service providers.
As above, industry support by itself is a testament to the quality. After the prolonged hiatus, the event promises better, newer, and more value-packed beyond three-days.
The team welcomes online and onsite participants and is confident that the event will generate great learning value for attendees.